Core Viewpoint - The company Baiotai (688177) has signed a licensing and commercialization agreement with STADA Arzneimittel AG for the exclusive commercialization rights of its BAT1806 (Tocilizumab) injection in various regions, aiming to enhance its global strategy and core competitiveness [1] Group 1: Agreement Details - The total amount for the transaction, including upfront and milestone payments, can reach up to €136 million, comprising an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million [1] - The agreement also includes a revenue-sharing model based on a double-digit percentage of net sales [1] Group 2: Strategic Implications - The signing of this agreement is intended to rapidly convert the company's research and development achievements into economic benefits through commercial cooperation and licensing [1] - The collaboration with STADA is expected to integrate advantages in advanced research, production quality control, technology enhancement, clinical application, and commercial promotion, creating favorable conditions for the company's global strategy [1]

Core Viewpoint - Fosun Pharma's stock opened over 7% higher, reflecting positive market sentiment following the licensing agreement with Expedition Therapeutics for the development of DPP-1 inhibitor XH-S004 outside of China and Hong Kong [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., signed a licensing agreement with Expedition Therapeutics for the global development, production, and commercialization rights of DPP-1 inhibitor XH-S004, excluding China and Hong Kong [1] - Under the agreement, Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments based on development progress, with potential sales milestone payments of up to $525 million based on annual net sales in the licensed regions [1] Group 2: Clinical Trial Status - XH-S004 is currently in Phase II clinical trials for the treatment of non-cystic fibrosis bronchiectasis in China and in Phase Ib clinical trials for chronic obstructive pulmonary disease (COPD) [1]